Table 2.
Factors associated with progression-free survival and overall survival
| Variable | Progression-free survival |
Overall survival |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariate |
Univariate |
Multivariate |
|||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Helper T cell density > median | 0.52 (0.26-1.02) | 0.058 | 0.35 (0.17-0.74) | 0.005 | 0.42 (0.21-0.85) | 0.016 | 0.34 (0.17-0.71) | 0.004 |
| Age | 1.00 (0.97-1.03) | 0.947 | - | - | 1.00 (0.97-1.04) | 0.893 | - | - |
| Male sex | 0.90 (0.46-1.75) | 0.749 | - | - | 0.83 (0.42-1.64) | 0.598 | - | - |
| Measurable diseasea) | 1.06 (0.5-2.21) | 0.887 | - | - | 1.32 (0.63-2.76) | 0.466 | - | - |
| Initially stage IV | 1.27 (0.60-2.69) | 0.536 | - | - | 1.02 (0.50-2.11) | 0.951 | - | - |
| ECOG PS ≥ 2 | 3.12 (1.51-6.43) | 0.002 | 4.25 (1.95-9.26) | < 0.001 | 2.40 (1.19-4.80) | 0.014 | 2.91 (1.42-5.96) | 0.004 |
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazards ratio; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors.
a)
Measurable disease by RECIST.